Compare Citius Pharmaceuticals Inc (CTXR) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.11. The key difference: YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | GPTY | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $50.52 |
52-Week Low | $0.48 | $34.73 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
GPTY trades at $43.11, up 1.07% with a bullish technical signal supported by moving averages. The YieldMax AI & Tech Portfolio Option Income ETF demonstrates consistent weekly dividend distributions, with recent payouts ranging from $0.28-$0.37. Technical indicators show strong momentum with RSI at 83.06 suggesting potential overbought conditions, while support and resistance cluster around $42-$43 levels.
The ETF's strategy of harvesting options premiums from AI and semiconductor stocks provides high yield exposure, though the concentrated tech focus and elevated RSI levels warrant caution. Recent analysis highlights GPTY's balance of income generation and capital preservation compared to peers, but dependence on semiconductor momentum presents volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
